Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Zanubrutinib
Brand Name Brukinsa™
Payment Category Medicare Part D
Year Introduced 2019
Type of Drug Kinase inhibitor
Manufacturer Beigene USA Inc.

FDA-Approved Indication(s)

  • Indicated for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. (11/14/19)

Approved Indication(s) with Orphan Drug Status Treatment of mantle cell lymphoma.
ICD-10 Code(s) for Labeled Indication(s) Mantle cell lymphoma [C83.1x]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949